These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1175 related articles for article (PubMed ID: 25239345)

  • 21. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.
    Ansari D; Kristoffersson S; Andersson R; Bergenfeldt M
    Scand J Gastroenterol; 2017 Nov; 52(11):1165-1171. PubMed ID: 28687047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas.
    Dunki-Jacobs EM; Philips P; Martin RC
    J Am Coll Surg; 2014 Feb; 218(2):179-87. PubMed ID: 24315888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study.
    Tasu JP; Herpe G; Damion J; Richer JP; Debeane B; Vionnet M; Rouleau L; Carretier M; Ferru A; Ingrand P; Tougeron D
    Eur Radiol; 2024 Oct; 34(10):6885-6895. PubMed ID: 38494526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure.
    Zimmermann FB; Schuhmacher C; Lersch C; Bernhardt B; Pickel P; Siewert JR; Molls M; Jeremic B
    Hepatogastroenterology; 2004; 51(60):1842-6. PubMed ID: 15532839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension.
    Bachellier P; Rosso E; Fuchshuber P; Addeo P; David P; Oussoultzoglou E; Lucescu I
    Surgery; 2014 Mar; 155(3):449-56. PubMed ID: 24462078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status.
    Mullinax JE; Hernandez JM; Toomey P; Villadolid D; Bowers C; Cooper J; Rosemurgy AS
    Am J Surg; 2012 Nov; 204(5):704-8. PubMed ID: 23140830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.
    Rau BM; Moritz K; Schuschan S; Alsfasser G; Prall F; Klar E
    Surgery; 2012 Sep; 152(3 Suppl 1):S103-11. PubMed ID: 22766366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis.
    Lim JS; Heard J; Brant N; Malo J; Kong J; Osman H; Buell J; Jeyarajah DR
    Ann Surg Oncol; 2024 Nov; 31(12):8298-8307. PubMed ID: 39080139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head.
    Ohigashi H; Ishikawa O; Eguchi H; Sasaki Y; Yamada T; Noura S; Murata K; Takachi K; Miyashiro I; Doki Y; Imaoka S; Kasugai T; Nishiyama K
    Ann Surg Oncol; 2005 Aug; 12(8):629-36. PubMed ID: 15968497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy].
    Rau HG; Wichmann MW; Wilkowski R; Heinemann V; Sackmann M; Helmberger T; Dühmke E; Schildberg FW
    Chirurg; 2002 Feb; 73(2):132-7. PubMed ID: 11974476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
    Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
    J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.
    Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR
    Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.